Last reviewed · How we verify
Topical ocular hypotensive eye drops.
Topical ocular hypotensive eye drops. is a Carbonic anhydrase inhibitor Small molecule drug developed by Washington University School of Medicine. It is currently in Phase 3 development for Glaucoma, Ocular hypertension.
Reduces intraocular pressure by decreasing aqueous humor production.
Reduces intraocular pressure by decreasing aqueous humor production. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | Topical ocular hypotensive eye drops. |
|---|---|
| Sponsor | Washington University School of Medicine |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Topical ocular hypotensive eye drops work by decreasing the production of aqueous humor in the eye, thereby reducing intraocular pressure. This is typically achieved through the inhibition of carbonic anhydrase or the reduction of prostaglandin synthesis.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Blepharitis
- Dry eye
- Headache
Key clinical trials
- Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy (NA)
- A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma (PHASE4)
- Comparison of Topical Anesthesia and Analgosedation in Micropulse Transscleral Glaucoma Treatment (NA)
- Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents (PHASE4)
- The Effect of Topical Brimonidine on the Ocular Hemodynamics in Patients of POAG Using OCTA (PHASE4)
- PSLT Compared to Prostaglandin Analogue Eye Drops (NA)
- Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical ocular hypotensive eye drops. CI brief — competitive landscape report
- Topical ocular hypotensive eye drops. updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI
Frequently asked questions about Topical ocular hypotensive eye drops.
What is Topical ocular hypotensive eye drops.?
How does Topical ocular hypotensive eye drops. work?
What is Topical ocular hypotensive eye drops. used for?
Who makes Topical ocular hypotensive eye drops.?
What drug class is Topical ocular hypotensive eye drops. in?
What development phase is Topical ocular hypotensive eye drops. in?
What are the side effects of Topical ocular hypotensive eye drops.?
What does Topical ocular hypotensive eye drops. target?
Related
- Drug class: All Carbonic anhydrase inhibitor drugs
- Target: All drugs targeting Carbonic anhydrase
- Manufacturer: Washington University School of Medicine — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Glaucoma
- Indication: Drugs for Ocular hypertension
- Compare: Topical ocular hypotensive eye drops. vs similar drugs
- Pricing: Topical ocular hypotensive eye drops. cost, discount & access